Coherus BioSciences Inc. is betting big on biosimilars, and is one of an elite group of pure play biosimilar specialists looking to compete against significantly bigger players. Though Coherus is a relatively little-known newcomer, it is one of just seven drug companies to have submitted a biosimilar application to FDA, along with marquee names like Sandoz Inc., Amgen Inc. and Pfizer Inc. – and it has the chance to be first to market in some lucrative categories.
Coherus, In Ring As A Biosimilar Contender, Hopes To Smack Down Humira
Six-year-old biosimilar specialist could be first company to launch a biosimilar version of Neulasta, but the possibility of a biosimilar version of Humira has investors ogling.
More from Business
• By
The CEO of a South Korean state-run drug R&D support fund urges the renewal of the initiative as it increasingly focuses on new modalities and novel targets.
• By
Roivant president Eric Venker was named CEO of Immunovant to guarantee execution of the development plan for IMVT-1402 in six indications, now including Sjögren’s disease and cutaneous lupus erythematosus.
• By
As investors have begun to ask troubled drug developers to suspend operations and return remaining cash to shareholders, Alis has stepped forward with a new fund aiming to facilitate that.
More from Scrip
• By
As investors have begun to ask troubled drug developers to suspend operations and return remaining cash to shareholders, Alis has stepped forward with a new fund aiming to facilitate that.
• By
The company reported positive topline results for ASCENT-04, which also bode well for the ASCENT-03 trial in patients with low PD-L1 expression.
• By
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.